AI-ACCELERATED DRUG DISCOVERY

Diablo IAP-binding mitochondrial protein

Explore its Potential with AI-Driven Innovation
Predicted by Alphafold

Diablo IAP-binding mitochondrial protein - Focused Library Design

Available from Reaxense

This protein is integrated into the Receptor.AI ecosystem as a prospective target with high therapeutic potential. We performed a comprehensive characterization of Diablo IAP-binding mitochondrial protein including:

1. LLM-powered literature research

Our custom-tailored LLM extracted and formalized all relevant information about the protein from a large set of structured and unstructured data sources and stored it in the form of a Knowledge Graph. This comprehensive analysis allowed us to gain insight into Diablo IAP-binding mitochondrial protein therapeutic significance, existing small molecule ligands, relevant off-targets, and protein-protein interactions.

 Fig. 1. Preliminary target research workflow

2. AI-Driven Conformational Ensemble Generation

Starting from the initial protein structure, we employed advanced AI algorithms to predict alternative functional states of Diablo IAP-binding mitochondrial protein, including large-scale conformational changes along "soft" collective coordinates. Through molecular simulations with AI-enhanced sampling and trajectory clustering, we explored the broad conformational space of the protein and identified its representative structures. Utilizing diffusion-based AI models and active learning AutoML, we generated a statistically robust ensemble of equilibrium protein conformations that capture the receptor's full dynamic behavior, providing a robust foundation for accurate structure-based drug design.

 Fig. 2. AI-powered molecular dynamics simulations workflow

3. Binding pockets identification and characterization

We employed the AI-based pocket prediction module to discover orthosteric, allosteric, hidden, and cryptic binding pockets on the protein’s surface. Our technique integrates the LLM-driven literature search and structure-aware ensemble-based pocket detection algorithm that utilizes previously established protein dynamics. Tentative pockets are then subject to AI scoring and ranking with simultaneous detection of false positives. In the final step, the AI model assesses the druggability of each pocket enabling a comprehensive selection of the most promising pockets for further targeting.

 Fig. 3. AI-based binding pocket detection workflow

4. AI-Powered Virtual Screening

Our ecosystem is equipped to perform AI-driven virtual screening on Diablo IAP-binding mitochondrial protein. With access to a vast chemical space and cutting-edge AI docking algorithms, we can rapidly and reliably predict the most promising, novel, diverse, potent, and safe small molecule ligands of Diablo IAP-binding mitochondrial protein. This approach allows us to achieve an excellent hit rate and to identify compounds ready for advanced lead discovery and optimization.

 Fig. 4. The screening workflow of Receptor.AI

Receptor.AI, in partnership with Reaxense, developed a next-generation technology for on-demand focused library design to enable extensive target exploration.

The focused library for Diablo IAP-binding mitochondrial protein includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

Diablo IAP-binding mitochondrial protein

partner:

Reaxense

upacc:

Q9NR28

UPID:

DBLOH_HUMAN

Alternative names:

Diablo homolog, mitochondrial; Direct IAP-binding protein with low pI; Second mitochondria-derived activator of caspase

Alternative UPACC:

Q9NR28; B2RDQ0; Q6W3F3; Q96LV0; Q9BT11; Q9HAV6

Background:

Diablo IAP-binding mitochondrial protein, also known as Diablo homolog, mitochondrial, Direct IAP-binding protein with low pI, and Second mitochondria-derived activator of caspase, plays a pivotal role in promoting apoptosis. It activates caspases in the cytochrome c/Apaf-1/caspase-9 pathway, countering the inhibitory activity of IAPs and facilitating the degradation of XIAP/BIRC4 through the ubiquitin-proteasome pathway.

Therapeutic significance:

Linked to Deafness, autosomal dominant, 64, due to its role in apoptosis, understanding Diablo IAP-binding mitochondrial protein's function could unveil new therapeutic strategies for sensorineural hearing loss and potentially other apoptosis-related disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.